DPP4 and heart failure: Furthermore, the neutral effect on heart failure hospitalizations in TECOS helped distinguish sitagliptin from saxagliptin and underscored the need for individualized consideration of DPP-4 inhibitors based on each drug’s cardiovascular profile.